LGC

EASI-Genomics was launched earlier this year to provide free access to NGS technologies and genomic services to researchers from industry and academia.

LGC said the acquisition will improve its position across the clinical quality control tools market and increase its proficiency testing offerings.

CoPrimers use a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker, which prevents the formation of primer-dimers.

LGC said that the acquisition will increase its presence in the nucleic acid market, in addition to its previous acquisitions in the last few years.

The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.

London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.

LGC will offer NuGen's single-primer enrichment technology for next-generation sequencing target enrichment.

LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.

The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.